N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, a worldwide leader in diagnostic imaging, today announces the initiation of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), a multi-center Phase IV observational study that will further evaluate the safety profile of DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension in patients with suboptimal echocardiograms and provide safety information on the use of ultrasound contrast agents in routine clinical practice.
